off-the-wire

UPDATE 1-FDA reviewers flag concerns over Sarepta's gene therapy for muscle-wasting disorder

Kitco Media
By Reuters
Published:
Updated:
Reuters
(Adds details in paragraphs 2 and 3) May 10 (Reuters) - Data presented for Sarepta Therapeutics Inc's experimental gene therapy for a muscle-wasting disorder did not provide unambiguous evidence that the treatment worked, the U.S. Food and Drug Administration's staff reviewers on Wednesday.


The company is seeking accelerated approval for the first gene therapy for Duchenne muscular dystrophy, based on data that showed it helped patients make a mini version of the dystrophin protein needed to keep muscle cells intact.


"Additionally, FDA has safety concerns related to the possibility of administering an ineffective gene therapy," the reviewers said in the briefing documents, ahead of a meeting of outside advisers to the drug agency on Friday.
(Reporting by Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila)

Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.